Vancomycin

Generic Name: Vancomycin

Brand Names: Firvanq, Vancocin

Drug Type: Small Molecule

Chemical Formula: C_₆₆H_₇₅Cl_₂N_₉O_₂₄

CAS Number: 1404-90-6

Unique Ingredient Identifier: 6Q205EH1VU

Background: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].

Indication: Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).

Associated Conditions: Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection

Clinical Trials

A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients

Phase 4

Not yet recruiting

Conditions: Acute Kidney Injury

Interventions: Drug: Vancomycin
Drug: Cefepime
Drug: Piperacillin-tazobactam

First Posted Date: 2025-05-01

Last Posted Date: 2025-05-01

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 750

Registration Number: NCT06954129

Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh

Phase 2

Not yet recruiting

Conditions: Environmental Enteric Dysfunction

Interventions: Drug: Placebo
Drug: VE818
Drug: Oral Vancomycin

First Posted Date: 2025-02-10

Last Posted Date: 2025-04-22

Lead Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh

Target Recruit Count: 144

Registration Number: NCT06817031

Locations: 🇧🇩
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Matlab, Bangladesh

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients with Inflammatory Bowel Disease

Phase 4

Not yet recruiting

Conditions: Inflammatory Bowel Disease (IBD)
Clostridioides Difficile Infection

Interventions: Drug: Vancomycin (POC)
Drug: Fidaxomicin

First Posted Date: 2025-01-27

Last Posted Date: 2025-02-05

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 60

Registration Number: NCT06794944

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty

Phase 2

Recruiting

Conditions: Primary Total Knee Arthroplasty
Intraosseous Morphine Injection
Knee Osteoarthritis

Interventions: Drug: Vancomycin
Drug: Morphine

First Posted Date: 2024-12-04

Last Posted Date: 2025-01-09

Lead Sponsor: Carilion Clinic

Target Recruit Count: 86

Registration Number: NCT06716749

Locations: 🇺🇸
Carilion Clinic, Roanoke, Virginia, United States

Clostridioides Difficile Controlled Human Infection Model

Not Applicable

Not yet recruiting

Conditions: C. Difficile
C. Difficile Infection
Controlled Human Infection

Interventions: Other: encapsulated 10^4 CFU toxigenic. C. difficile spores
Drug: Vancomycin
Drug: Clindamycin

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 60

Registration Number: NCT06702345

Locations: 🇳🇱
Leiden University Medical Center, Leiden, Zuid Holland, Netherlands

Daptomycin Vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

Phase 4

Recruiting

Conditions: Staphylococcus Aureus Septicemia
Staphylococcus Aureus Bacteremia
S. Aureus Bacteremia
S. Aureus Bloodstream Infection
Staphylococcus Aureus Endocarditis

Interventions: Drug: Daptomycin for Injection
Drug: Vancomycin (IV)

First Posted Date: 2024-10-15

Last Posted Date: 2024-11-27

Lead Sponsor: Todd C. Lee MD MPH FIDSA

Target Recruit Count: 300

Registration Number: NCT06637332

Locations: 🇨🇦
Fraser Health Authority (Surrey Memorial Hospital), Surrey, British Columbia, Canada
🇨🇦
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada

Vancomycin Dose Optimization in Obesity

Phase 1

Active, not recruiting

Conditions: Pharmacokinetics and Pharmacodynamics

Interventions: Drug: Vancomycin (IV)

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-07

Lead Sponsor: University of Michigan

Target Recruit Count: 24

Registration Number: NCT06601257

Locations: 🇺🇸
Michigan Clinical Research Unit, Ann Arbor, Michigan, United States

A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

Phase 1

Recruiting

Conditions: Ulcerative Colitis

Interventions: Biological: MB310
Other: Placebo
Drug: Vancomycin

First Posted Date: 2024-09-03

Last Posted Date: 2025-02-21

Lead Sponsor: Microbiotica Ltd

Target Recruit Count: 30

Registration Number: NCT06582264

Locations: 🇦🇹
Medizinische Universitaet Innsbruck, Innsbruck, Austria
🇦🇹
Klinikum Klagenfurt am Woerthersee, Klagenfurt, Austria
🇦🇹
Uniklinikum Salzburg, Salzburg, Austria

and more 15 locations